365mc Partners with Boehringer Ingelheim Korea to Raise Awareness of Liver Health in Patients with Obesity 👏

Hello,

this is LipoManiac 365.

365mc has signed a Memorandum of Understanding (MOU) with Boehringer Ingelheim Korea, a global pharmaceutical company.

This agreement was established to enhance awareness of the link between obesity and liver health, and to jointly develop and operate early diagnostic programs for liver disease targeting high-risk obesity groups.

The signing ceremony was attended by Namcheol Kim, CEO of 365mc Co., Ltd., and Anna-Maria Boy, President of Boehringer Ingelheim Korea, representing each organization.

It is reported that three out of ten Korean adults are affected by metabolic dysfunction–associated fatty liver disease, with particularly high prevalence among individuals with obesity or metabolic disorders.

As a result, the need for systematic management and early screening of high-risk groups continues to grow.

Since its establishment, 365mc has focused exclusively on fat treatment for over 23 years.

Building on its expertise in body contouring and obesity care, 365mc has consistently engaged in initiatives aimed at improving overall health awareness.

This partnership represents a continuation of those efforts.

Boehringer Ingelheim, headquartered in Germany, is a global pharmaceutical company dedicated to the development of treatments in cardiovascular and metabolic disease areas.

Boehringer Ingelheim Korea has been actively working to improve the treatment environment for chronic diseases within Korea.

Through this collaboration, both organizations will progressively implement initiatives to enhance liver health management and preventive awareness among patients with obesity, leveraging their respective areas of expertise.

365mc remains committed to promoting accurate health awareness and ensuring that everyday health practices can expand into meaningful social value.

Thank you.